{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-008325","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.937850+00:00","generated_at":"2026-05-16T05:56:32.607299+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028","bullets":["Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.","Pricing: common shares at $10.77 (most) and $12.13 for insiders; warrants exercisable at $14.40.","Warrants expire 60 days after PMN310 SAD topline data announcement or Feb 3, 2031.","Proceeds to fund Phase 1b Alzheimer's study and subcutaneous PMN310 development; blinded 6-month data expected mid-2026.","Co-led by Janus Henderson and Ally Bridge Group; CEO and board also participated."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-008325","json":"https://secwatch.observer/filing/0001104659-26-008325.json","markdown":"https://secwatch.observer/filing/0001104659-26-008325.md","text":"https://secwatch.observer/filing/0001104659-26-008325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:56:32.607299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0382a54c21e47309ae1ea64519326bb59bad2c3c","claim":"ProMIS Neurosciences Inc. entered into Registration Rights Agreement with each of the PIPE Investors.","evidence_excerpt":"In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with each of the PIPE Investors (the “ Registration Rights Agreement ”), pursuant to which the Company is required to prepare and file a registration statement (the “ Registration Statement ”) with the Securities and Exchange Commission (the “ SEC ”) under the Securities Act, covering the resale of the Common Shares issued to the PIPE Investors under the Securities Purchase Agreement, together with the Warrant Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"each of the PIPE Investors"}],"fact_type":"material_agreement"},{"claim_id":"1e907e0f894e38f457cde71ef728c5e2d4775bce","claim":"ProMIS Neurosciences Inc. entered into Securities Purchase Agreement with selected investors that qualify as \"accredited investors\" valued at approximately $75 million (effective 2026-01-29).","evidence_excerpt":"On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"selected investors that qualify as \"accredited investors\""},{"label":"Value","value":"approximately $75 million"},{"label":"Effective","value":"2026-01-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}